{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:18Z","timestamp":1792806198784,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>A recent Organ Procurement and Transplant Network policy change removes hepatitis C virus (HCV) status and race from the Kidney Donor Profile Index (KDPI) calculation, thereby lowering the KDPI of HCV nucleic acid testing positive (NAT<jats:sup>+<\/jats:sup>) kidneys and increasing their allocation priority. However, even in the era of direct-acting antivirals, high KDPI HCV NAT<jats:sup>+<\/jats:sup> kidneys exhibited higher discard rates compared with their HCV NAT<jats:sup>\u2013<\/jats:sup> counterparts, and outcome data for this \u201chigh-risk\u201d group remain limited. This study aims to address this knowledge gap by providing comprehensive outcome data to better inform organ allocation and selection decisions under the new KDPI framework.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Using national transplant data from 2015 to 2023, we analyzed adult deceased donor kidney transplants stratified by KDPI and HCV NAT status. An exact matching model was used to identify the matched HCV NAT<jats:sup>\u2013<\/jats:sup> group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>No significant differences were observed in delayed graft function, rejection, or patient and graft survival between high KDPI HCV NAT<jats:sup>+<\/jats:sup> and matched HCV NAT<jats:sup>\u2013<\/jats:sup> recipients. High KDPI HCV NAT<jats:sup>+<\/jats:sup> kidneys were more often allocated regionally or nationally, with 67.6% occurring in 4 regions. Their recipients were more likely to have a high school education and shorter wait times. After the policy change, &gt;90% of prior high KDPI HCV NAT<jats:sup>+<\/jats:sup> kidneys will no longer be classified as high KDPI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Our findings support the safe utilization of previously high KDPI HCV NAT<jats:sup>+<\/jats:sup> kidneys after a policy change. Although the revised KDPI may assist clinicians in identifying higher-quality organs, its impact on existing sociodemographic disparities and overall organ utilization rate remains uncertain.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001827","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T21:00:09Z","timestamp":1751058009000},"page":"e1827","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of High Kidney Donor Profile Index Hepatitis C Nucleic Acid Testing Positive Kidneys are Equivalent to Matched Hepatitis C Nucleic Acid Testing Negative Kidneys"],"prefix":"10.1097","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-5664","authenticated-orcid":false,"given":"Shengliang","family":"He","sequence":"first","affiliation":[{"name":"Division of Transplant and Hepatobiliary Surgery, Department of Surgery, Organ Transplant Center, University of Iowa Hospital and Clinics, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie P.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA."},{"name":"VA Medical Center, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan E.","family":"Gunderson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Iowa Hospital and Clinics, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ten Eyck","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan I.","family":"Reed","sequence":"additional","affiliation":[{"name":"Division of Transplant and Hepatobiliary Surgery, Department of Surgery, Organ Transplant Center, University of Iowa Hospital and Clinics, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"R1-20250714","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/j.ajkd.2022.12.019","article-title":"Kidney transplantation from hepatitis C virus-infected donors to uninfected recipients: a systematic review for the KDIGO 2022 hepatitis C clinical practice guideline update.","volume":"82","author":"Gordon","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R2-20250714","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.kint.2021.06.034","article-title":"A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients.","volume":"100","author":"Daloul","year":"2021","journal-title":"Kidney Int"},{"key":"R3-20250714","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jama.2022.12868","article-title":"Five-year allograft survival for recipients of kidney transplants from hepatitis C virus infected vs uninfected deceased donors in the direct-acting antiviral therapy era.","volume":"328","author":"Schaubel","year":"2022","journal-title":"JAMA"},{"key":"R4-20250714","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients.","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20250714","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial.","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"R6-20250714","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOT.0000000000001031","article-title":"Utilization of hepatitis C virus-positive donors in kidney transplantation.","volume":"28","author":"Shetty","year":"2023","journal-title":"Curr Opin Organ Transplant"},{"issue":"2s1","key":"R7-20250714","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ajt.2024.01.012","article-title":"OPTN\/SRTR 2022 annual data report: kidney.","volume":"24","author":"Lentine","year":"2024","journal-title":"Am J Transplant"},{"key":"R8-20250714","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0b013e3181ac620b","article-title":"A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index.","volume":"88","author":"Rao","year":"2009","journal-title":"Transplantation"},{"key":"R9-20250714","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.suc.2013.08.007","article-title":"The kidney allocation system.","volume":"93","author":"Friedewald","year":"2013","journal-title":"Surg Clin North Am"},{"key":"R10-20250714","article-title":"Race and hepatitis C status no longer included in calculation used to estimate deceased donor kidney function; policy change anticipated to increase equity."},{"key":"R11-20250714","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ekir.2021.11.022","article-title":"One-year outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.","volume":"7","author":"Sise","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R12-20250714","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ajt.2022.11.005","article-title":"The association of donor hepatitis C virus infection with 3-year kidney transplant outcomes in the era of direct-acting antiviral medications.","volume":"23","author":"Sutcliffe","year":"2023","journal-title":"Am J Transplant"},{"key":"R13-20250714","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1111\/ajt.15496","article-title":"Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.","volume":"19","author":"La Hoz","year":"2019","journal-title":"Am J Transplant"},{"key":"R14-20250714","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.10960720","article-title":"Trends in discard of kidneys from hepatitis C viremic donors in the United States.","volume":"16","author":"Chang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"R15-20250714","doi-asserted-by":"crossref","first-page":"e15323","DOI":"10.1111\/ctr.15323","article-title":"Transplant surgeons already account for inaccuracies in the Kidney Donor Profile Index (KDPI) calculation.","volume":"38","author":"Guan","year":"2024","journal-title":"Clin Transplant"},{"key":"R16-20250714","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation.","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"R17-20250714","article-title":"Refit kidney donor profile indexwithout race and hepatitis C virus."},{"key":"R18-20250714"},{"key":"R19-20250714","doi-asserted-by":"crossref","first-page":"33","DOI":"10.37737\/ace.22005","article-title":"Introduction to matching in case-control and cohort studies.","volume":"4","author":"Iwagami","year":"2022","journal-title":"Ann Clin Epidemiol"},{"issue":"4 Pt 2","key":"R20-20250714","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1600-6135.2005.00840.x","article-title":"Transplant data: sources, collection and research considerations, 2004.","volume":"5","author":"Dickinson","year":"2005","journal-title":"Am J Transplant"},{"key":"R21-20250714","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/TP.0000000000004630","article-title":"Mitigating health disparities in transplantation requires equity, not equality.","volume":"108","author":"Reed","year":"2024","journal-title":"Transplantation"},{"key":"R22-20250714","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.kint.2018.12.021","article-title":"Limited health literacy is associated with reduced access to kidney transplantation.","volume":"95","author":"Taylor","year":"2019","journal-title":"Kidney Int"},{"key":"R23-20250714","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.ajkd.2008.01.019","article-title":"Educational level as a determinant of access to and outcomes after kidney transplantation in the United States.","volume":"51","author":"Schaeffner","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R24-20250714","doi-asserted-by":"crossref","first-page":"c33","DOI":"10.1159\/000319645","article-title":"Factors associated with nonadherence to medication in kidney transplant recipients.","volume":"117","author":"Goldfarb-Rumyantzev","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R25-20250714","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/TP.0000000000002383","article-title":"Socioeconomic status and kidney transplant outcomes in a Universal Healthcare System: a population-based cohort study.","volume":"103","author":"Naylor","year":"2019","journal-title":"Transplantation"},{"key":"R26-20250714","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.transproceed.2024.03.042","article-title":"Regional differences and temporal changes in the utilization of HCV-viremic donors in kidney transplantation.","volume":"56","author":"Leeaphorn","year":"2024","journal-title":"Transplant Proc"},{"key":"R27-20250714","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1097\/TXD.0000000000001222","article-title":"Clinical and financial implications of 2 treatment strategies for donor-derived hepatitis C infections.","volume":"7","author":"Stewart","year":"2021","journal-title":"Transplant Direct"},{"key":"R28-20250714","doi-asserted-by":"crossref","first-page":"e761","DOI":"10.1097\/TXD.0000000000001217","article-title":"Kidney transplantation from hepatitis C viremic deceased donors to aviremic recipients in a real-world setting.","volume":"7","author":"Concepcion","year":"2021","journal-title":"Transplant Direct"},{"key":"R29-20250714","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1097\/TXD.0000000000001056","article-title":"Financial evaluation of kidney transplant with hepatitis C viremic donors to uninfected recipients.","volume":"6","author":"Axelrod","year":"2020","journal-title":"Transplant Direct"},{"key":"R30-20250714","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/ajt.17197","article-title":"Deceased donor kidneys are discarded at higher rates when labeled as high kidney donor profile index.","volume":"22","author":"Crannell","year":"2022","journal-title":"Am J Transplant"},{"key":"R31-20250714","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1111\/ajt.14379","article-title":"New insights into the alleged kidney donor profile index labeling effect on kidney utilization.","volume":"17","author":"Stewart","year":"2017","journal-title":"Am J Transplant"},{"key":"R32-20250714","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/ajt.15583","article-title":"Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: a unique complication in the DAA era.","volume":"20","author":"Kapila","year":"2020","journal-title":"Am J Transplant"},{"key":"R33-20250714","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2022.12.006","article-title":"Antiviral treatment failures after transplantation of organs from donors with hepatitis C infection: a report of 4 cases.","volume":"82","author":"Steinbrink","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R34-20250714","doi-asserted-by":"crossref","first-page":"p1245","DOI":"10.1016\/j.ajt.2025.01.015","article-title":"Updating the kidney donor risk index: removing donor race and hepatitis C virus status.","volume":"25","author":"Miller","year":"2025","journal-title":"Am J Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:00:29Z","timestamp":1752512429000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001827","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}